CHARLES V. SANDERS, M.D.; RICHARD N. GREENBERG, M.D.; ROBERT L. MARIER, M.D.
SANDERS CV, GREENBERG RN, MARIER RL. Cefamandole and Cefoxitin. Ann Intern Med. 1985;103:70-78. doi: 10.7326/0003-4819-103-1-70
Download citation file:
Published: Ann Intern Med. 1985;103(1):70-78.
Cefamandole and cefoxitin, introduced only 7 years ago, are now the most commonly prescribed parenteral antibiotics in the United States. These drugs are similar to the first-generation cephalosporins in toxicity, but their in-vitro spectrum of activity is greater. Their serum half-lives are longer than those of cephalothin and cephapirin but shorter than that of cefazolin. Although cefamandole has been recommended in empiric therapy for patients with community-acquired pneumonia and as a prophylactic agent for patients having various surgical procedures, other regimens are less expensive and just as effective. Cefamandole should not be used to treat intra-abdominal, enterobacter, or ampicillin-resistant Haemophilus influenzae infections. Cefoxitin is effective in the treatment and prevention of mixed aerobic-anaerobic skin and soft-tissue, intra-abdominal, gynecologic, and penicillinase-producing, spectinomycin-resistant Neisseria gonorrhoeae infections. Cefoxitin represents a greater advance than cefamandole in our continuing search for safe and more effective antimicrobial agents.
Learn more about subscription options.
Register Now for a free account.
Emergency Medicine, Infectious Disease, Pulmonary/Critical Care, Pneumonia, Sexually Transmitted Infections.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only